ASH 2023 | Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the first real-world study of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL), using data extracted from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. Based on the findings of previous clinical trials, liso-cel is known to be an effective treatment for R/R LBCL, and the therapy continued to show activity in this real-world population. Toxicities were manageable and uncommon, and safety and efficacy were not compromised by age or eligibility for the TRANSFORM study (NCT03575351). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
